Health Care & Life Sciences » Biotechnology | Aptevo Therapeutics Inc.

Aptevo Therapeutics Inc. | Income Statement

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
170.00
45,631.00
33,601.00
9,985.00
14,658.00
23,067
Cost of Goods Sold (COGS) incl. D&A
666.00
16,254.00
16,933.00
12,467.00
5,010.00
11,214
Gross Income
496.00
29,377.00
16,668.00
2,482.00
9,648.00
11,853
SG&A Expense
52,859.00
97,669.00
77,768.00
65,278.00
63,597.00
63,518
EBIT
53,355.00
68,292.00
-
-
53,949.00
51,665
Unusual Expense
-
-
-
71,013.00
-
-
Non Operating Income/Expense
18.00
222.00
237.00
810.00
1,944.00
2,024
Pretax Income
53,337.00
68,514.00
61,337.00
139,583.00
55,893.00
53,689
Income Tax
-
17,399.00
2,020.00
19,692.00
23,301.00
-
Consolidated Net Income
53,337.00
51,115.00
59,317.00
119,891.00
32,592.00
53,689
Net Income
53,337.00
51,115.00
59,317.00
119,891.00
32,592.00
53,689
Net Income After Extraordinaries
53,337.00
51,115.00
59,317.00
127,367.00
72,157.00
53,689
Net Income Available to Common
53,337.00
51,115.00
59,317.00
112,415.00
45,724.00
53,689
EPS (Basic)
-
2.52
2.93
5.55
0.33
2.39
Basic Shares Outstanding
-
20,248.80
20,248.80
20,239.20
21,335.20
22,500.10
EPS (Diluted)
-
2.52
2.93
5.55
0.33
2.39
Diluted Shares Outstanding
-
20,248.80
20,248.80
20,239.20
21,335.20
22,500.10
EBITDA
52,689.00
66,271.00
58,193.00
65,860.00
51,649.00
49,275

About Aptevo Therapeutics

View Profile
Address
2401 4th Avenue
Seattle Washington 98121
United States
Employees -
Website http://aptevotherapeutics.com
Updated 07/08/2019
Aptevo Therapeutics, Inc. is a biotechnology company, which engages in the discovery, development, commercialization and sale of novel oncology and hematology therapeutics. Its pipeline includes Otlertuzumab, APVO414, APVO436, ROR1 Candidate, and ALG. APV-527.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.